ArticleBlood2012
Systematic analysis of microRNA fingerprints in thrombocythemic platelets using integrated platforms.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Biliverdin reductase B as a new target in breast cancer.Breast cancer research : BCR · 2025Article
- Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo.Nature communications · 2025Article
- Deconvolution of the tumor-educated platelet transcriptome reveals activated platelet and inflammatory cell transcript signatures.JCI insight · 2024Article
- Age-restricted functional and developmental differences of neonatal platelets.Journal of thrombosis and haemostasis : JTH · 2022Article
- Cytokine pathway variants modulate platelet production: IFNA16 is a thrombocytosis susceptibility locus in humans.Blood advances · 2022Article
- Proteomics: A Tool to Study Platelet Function.International journal of molecular sciences · 2021Review
- Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis.Annals of translational medicine · 2020Article
- ccf-mtDNA as a Potential Link Between the Brain and Immune System in Neuro-Immunological Disorders.Frontiers in immunology · 2019Review
- Article
- Translational Implications of Platelets as Vascular First Responders.Circulation research · 2018Review
- Article
- BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans.Blood · 2016Article
- MicroRNAs as regulatory elements in immune system logic.Nature reviews. Immunology · 2016Review
- miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.Blood cancer journal · 2016Article
- Platelets miRNA as a Prediction Marker of Thrombotic Episodes.Disease markers · 2016Review
- MicroRNAs in platelet function and cardiovascular disease.Nature reviews. Cardiology · 2015Review
- microRNA regulation of Wnt signaling pathways in development and disease.Cellular signalling · 2015Review
- miR-142 orchestrates a network of actin cytoskeleton regulators during megakaryopoiesis.eLife · 2014Article
- MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression.PloS one · 2014Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Posttranscriptional and translational controls mediated by microRNAs (miRNA) regulate diverse biologic processes. We dissected regulatory effects of miRNAs relevant to megakaryocytopoiesis and platelet biology by analyzing expression patterns in 79 subjects with thrombocytosis and controls, and integrated data with transcriptomic and proteomic platforms. We validated a unique 21-miRNA genetic fingerprint associated with thrombocytosis, and demonstrated that a 3-member subset defines essential thrombocythemia (ET). The genetic signature includes functional guide and passenger strands of the previously uncharacterized miR 490 (5p and 3p), which displayed restricted, low-level expression in megakaryocytes/platelets (compared with leukocytes), and aberrant expression during thrombocytosis, most profound in ET. Overexpression of miR 490 in a bilineage differentiation model of megakaryocyte/erythroid progenitor formation was insufficient for hematopoietic colony differentiation and/or lineage specification. Integration of transcriptomic and mass spectrometric datasets with functional reporter assays identified dishevelled associated activator of morphogenesis 1 (DAAM1) as a miR 490 5p protein target demonstrating decreased expression in ET platelets, putatively by translational control (and not by mRNA target degradation). Our data define a dysregulated miRNA fingerprint in thrombocytosis and support a developmentally restricted function of miR 490 (and its putative DAAM1 target) to conditions associated with exaggerated megakaryocytopoiesis and/or proplatelet formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.